We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+57.48%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$514M
AUM Growth
-$7.79M
Cap. Flow
-$48M
Cap. Flow %
-9.34%
Top 10 Hldgs %
56.23%
Holding
206
New
96
Increased
32
Reduced
19
Closed
50

Top Buys

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$11.2M
2
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$11.1M
3
ASXC
Asensus Surgical, Inc.
ASXC
+$8.33M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$8.2M
5
WIMI
WiMi Hologram Cloud
WIMI
+$8.14M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.5M
2
AZN icon
AstraZeneca
AZN
+$18.2M
3
MRNA icon
Moderna
MRNA
+$12.1M
4
XWEL icon
XWELL
XWEL
+$6.41M
5
CVM icon
CEL-SCI Corp
CVM
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 13.44%
2 Technology 2.48%
3 Consumer Staples 2.16%
4 Communication Services 1.48%
5 Financials 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHIP icon
51
Seanergy Maritime Holdings
SHIP
$348M
$2.11M 0.41%
+199,478
New +$2.29M
OCUL icon
52
PUT
Ocular Therapeutix
OCUL
$1.85B
$2.02M 0.39%
+1,230
New +$23.7K
IONS icon
53
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$1.92M 0.37%
428
– –
AGTC
54
PUT
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.91M 0.37%
+3,775
New +$19.6K
TCDA
55
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.88M 0.37%
354,755
+154,318
+77% +$970K
AFIB
56
DELISTED
Acutus Medical Inc
AFIB
$1.77M 0.34%
132,522
+55,022
+71% +$1.24M
ORMP icon
57
PUT
Oramed Pharmaceuticals
ORMP
$171M
$1.71M 0.33%
1,686
+695
+70% +$5.7K
INFI
58
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.71M 0.33%
+530,000
New +$1.77M
BCLI
59
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.69M 0.33%
295
+137
+87% +$10.3K
KUST
60
PUT
Kustom Entertainment Inc
KUST
$639K
– –
0
– –
XELA
61
DELISTED
Exela Technologies, Inc. Common Stock
XELA
$1.64M 0.32%
+188
New +$1.89M
VINC
62
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.6M 0.31%
+4,147
New +$1.67M
OCUL icon
63
CALL
Ocular Therapeutix
OCUL
$1.85B
$1.58M 0.31%
+966
New +$18.6K
AMPGW
64
DELISTED
Amplitech Group Warrants
AMPGW
$1.5M 0.29%
+342,425
New +$1.04M
PRFX icon
65
PRF Technologies Ltd
PRFX
$3.25M
$1.46M 0.28%
275
+224
+439% +$1.35M
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.46M 0.28%
8,500
+5,500
+183% +$1.09M
DXR icon
67
Daxor
DXR
$62.2M
$1.44M 0.28%
118,736
-9,662
-8% -$122K
ADTX
68
PUT
DELISTED
ADITXT INC
ADTX
– –
0
– –
OPTT icon
69
PUT
Ocean Power Technologies
OPTT
$40.6M
$1.38M 0.27%
+4,153
New +$16K
ARKK icon
70
PUT
ARK Innovation ETF
ARKK
$5.74B
$1.37M 0.27%
+114
New +$15.4K
SAGE
71
PUT
DELISTED
Sage Therapeutics
SAGE
$1.24M 0.24%
+166
New +$13.6K
WIMI
72
PUT
WiMi Hologram Cloud
WIMI
$21M
$1.21M 0.24%
+184
New +$15.3K
XBI icon
73
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$1.19M 0.23%
+8,735
New +$1.31M
BPTS
74
DELISTED
Biophytis SA American Depositary Share (0.01 Euro)
BPTS
$1.18M 0.23%
+231
New +$1.38M
KUST
75
Kustom Entertainment Inc
KUST
$639K
$1.13M 0.22%
+1
New +$1.41M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sabby Management held 206 positions worth $514M, down 1.5% from $522M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sabby Management withdrew a net $48M in Q1 2021, closing 50 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $31.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Sorrento Therapeutics, Inc. worth $8.81M.

  • Sabby Management's largest Q1 2021 buy was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.
  • Sabby Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2021, an estimated $11.1M increase.
  • Sabby Management's biggest Q1 2021 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $494K.
  • Sabby Management fully exited Biogen in Q1 2021, selling an estimated $31.5M.
  • Sabby Management's ten largest holdings make up 56% of its $514M portfolio in Q1 2021.
  • Sabby Management opened 96 new positions and closed 50 in Q1 2021.
  • Sabby Management's portfolio value fell 1.5% quarter-over-quarter to $514M.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.